children's health Archives - Page 3 of 4 - Sanford Burnham Prebys
Institute News

Meet neuroscientist Paloma Sánchez Pavón

AuthorMonica May
Date

October 7, 2020

Paloma’s research aims to protect premature babies from brain damage

Newborns have a new scientist in their corner: Paloma Sánchez Pavón, a graduate student in the lab of Jerold Chun, MD, PhD Paloma is working to find a medicine that could protect the still-developing brains of premature babies, which are incredibly delicate and prone to swelling. Called hydrocephalus, the condition is common—affecting one in 1,000 newborns—and repeated brain surgery is the only treatment.

We caught up with Paloma to learn more about what makes her tick, including why she decided to become a scientist and what she wishes people knew about research.

  • Did you always know you wanted to be a scientist? When you were a child, did you ever imagine you would be in the role you are today?
    I always knew I wanted to become a scientist, but I didn’t imagine I would be in the position I am today. Growing up, I was obsessed with the idea of becoming a marine biologist. I was fascinated by how much we didn’t know about the ocean. My plan was to move closer to the beach and enroll in a program that would allow me to learn more about it. Nevertheless, I soon realized that I was both mesmerized and terrified of the ocean (sharks, especially), and that I would never be able to spend enough time diving and exploring the water, which is what such a career would require. I was still passionate about biology and science in general, so I decided to study the most unknown (and equally unexplored) organ in the human body—the brain.
  • What do you study, and what is your greatest hope for your research?

    I study hydrocephalus, a condition that often affects premature infants. These newborns are extremely fragile and often accumulate fluid in their heads, which can cause brain damage or death. The only treatment is invasive brain surgery, required multiple times throughout individuals’ lives, to insert a shunt in their brains and drain the excess fluid so it is reabsorbed somewhere else in the body. This procedure is extremely uncomfortable for the patients and, like any other surgery, is associated with several risks that endanger their lives. I’m trying to understand the disease so we can find a better, less invasive treatment.

Paloma Sánchez Pavón at the beach in front of the ocean at sunset

When Paloma isn’t working in the lab, she can be found enjoying one of San Diego’s many beautiful beaches

  • What is one scientific question you wish you had an absolutely true answer to?
    To answer this question, I will step away from biology and turn to the universe. What is there beyond our galaxy? Will we be able to inhabit other planets? If we have so many things to still learn about the ocean and the brain, the universe is in a completely different category, with so many possibilities ahead of us.
  • What do you wish people knew about science?
    That it is fun. Experiments are about testing limits and going beyond what is known. I think that is really exciting. Also, science advances because we’re constantly asking new questions. Curiosity is what keeps this field in continuous evolution. And never be afraid to ask questions because science can be understood by everybody—it just needs to be explained well.
  • When you aren’t working in the lab, where can you be found? Where is your happy place?
    You will find me at the beach, walking along it or watching a sunset. One of the main reasons why I decided to move to San Diego is because I fell in love with its sunsets. You will also find me having brunch (my favorite American tradition) with my friends or enjoying a beer after work with them, especially around Encinitas or downtown San Diego.
  • What is the best career advice you have ever received?
    Never stop pushing the boundaries of knowledge. A curious mind is what keeps a scientist passionate about their job. Experiments usually don’t work the first time. You have to keep asking new questions and learning from your mistakes. Finishing a project takes time, but every day is unexpected and exciting because you don’t know what you’re going to find. That is the thrilling part about being a scientist.
  • What do you wish people knew about Sanford Burnham Prebys?
    What a great community Sanford Burnham Prebys is. I’ve never been in such a collaborative environment, where you work closely not only with students and postdocs, but also with faculty members. Everyone is always willing to help, whether that is lending reagents or advising about different techniques. As a student, this is what I value the most because it helps me develop as a scientist in an extremely enriching way.

Learn more about our Graduate School of Biomedical Sciences.

Institute News

Rett Syndrome Foundation funds a potential cure

AuthorSusan Gammon
Date

April 23, 2020

The research may lead to a major step toward a cure.

Rett syndrome is a neurodevelopmental disorder that affects almost all aspects of a child’s life, from walking to eating to intellectual capability. There is no cure for the disease, which occurs mostly in girls, and treatments are aimed at slowing the loss of abilities and alleviating the debilitating symptoms. 

Jing Crystal Zhao, PhD, associate professor at Sanford Burnham Prebys, has received new funding from the Rett Syndrome Foundation to find ways to reverse the changes in a gene that causes Rett syndrome. The research may lead to a major step toward a cure.

“I’m very grateful to the Rett Syndrome Foundation, and excited to begin this project,” says Zhao. “While Rett syndrome may not be well known among the general public, our research may lead to treatments to improve the lives of patients around the world.”

More than 90% of Rett Syndrome cases are caused by genetic changes in a gene called MECP2. Every female carries two copies of the MECP2 gene. Rett syndrome patients carry both a normal and a mutant copy of MECP2. Unfortunately, in some cells, the normal copy of MEPC2 becomes inactive due to a biological process called X-chromosome inactivation—a process that occurs in females—and this leads to Rett syndrome. 

“Recent studies suggest that reversing X-chromosome inactivation could reactivate the normal copy of the MECP2 gene,” says Zhao. “We have identified an DNA element that plays a key role in X-chromosome inactivation. We are now going to test if we can block this element and restore the silent MECP2 gene, which could be life changing. 

“Our aim is to help individuals regain the skills and abilities stolen by Rett syndrome,” adds Zhao. “This award takes us closer to that goal.” 
 

Institute News

The one-of-a-kind kid

AuthorMonica May
Date

March 16, 2020

11-year-old Damian Omler is the only known individual with his CDG mutation.

Donnie and Gracie Omler are used to the question, “What’s wrong with your son?” Now, they don’t have to say, “We don’t know.”

While the Omlers knew that something was off when their son Damian started to miss his early milestones—he struggled to sit up, make “goo-goo” sounds and put weight on his legs—a decade passed before they had an official diagnosis.

Doctors suspected Damian had a congenital disorder of glycosylation, or CDG, but couldn’t confirm the mutation type. The family began attending Sanford Burnham Prebys’ Rare Disease Day Symposiums, but unanswered questions made them unsure of how they fit into the CDG community.

Now, the Omler family has answers. Hudson Freeze, PhD, and his team determined that Damian has a never-before-seen type of CDG, now named CDG-GET4. This gene codes for a chaperone protein that guides other proteins to where they need to be in a cell. Freeze’s team found that in Damian’s case, one of these chaperone proteins was almost completely gone.

“After the diagnosis we sat and smiled for a long time,” says Donnie. “Obviously we are not done. But answers give us hope. There might be a treatment or supplement for Damian. We might be able to predict possible complications in the future.”

The Omler’s shared with KPBS how receiving answers changed their life.

Today, Donnie and Gracie focus on giving Damian a fulfilling life. He attends school, where he has friends and participates in sports. He plays with his 9-year-old brother, DJ. He loves rock music—and even attempted to strum a guitar recently. Donnie, a rock lover himself, clutches his heart with joy when describing this development.

Still, the Omlers recognize the challenges that Damian faces. He has seizures, needs help using the restroom and recently got a feeding tube. They attend the Institute’s symposiums to make sure they are up-to-date on information that might help Damian. They also fundraise as much as possible to help researchers do more.

“We are amazed at how much brainpower it takes to find a diagnosis, let alone treat the disease,” says Donnie. “There is no way we could have done this alone. Without these scientists, we would probably still be waiting for answers.”

Institute News

Families, physicians and scientists unite at Sanford Burnham Prebys’ 11th Annual Rare Disease Day Symposium

AuthorMonica May
Date

March 16, 2020

This year’s event centered on CDG, a rare genetic condition that affects around 1,500 people worldwide.

With more than 270 attendees and 30 world-renowned scientists and clinicians, Sanford Burnham Prebys’ 11th Annual Rare Disease Day Symposium was officially the largest in the event’s history. This year’s discussion centered on congenital disorders of glycosylation, or CDG, a rare genetic condition that affects around 1,500 people worldwide.

Malin Burnham, T. Denny Sanford and Debra Turner, honorary trustees of Sanford Burnham Prebys, opened the three-day meeting with moving remarks. A theme emerged: Medical advances are accelerated when key stakeholders work together—including scientists, physicians, people with CDG and their families, patient advocacy groups, granting agencies, industry and philanthropists.

“Our annual symposium aims to create an ecosystem in which key stakeholders can collaborate and communicate,” said Hudson Freeze, PhD, director of the Human Genetics Program at Sanford Burnham Prebys and symposium chair. “Together, we celebrate our successes, focus on challenges and discuss the future of CDG research.”

Presenters at the meeting described the power of the ecosystem. Since the first conference a decade ago where scientists reported on the basic biology of CDGs, today we have promising clinical trials for the most common CDG mutation. In addition, a historic nationwide effort to establish the natural history of CDGs launched this year—which addresses decades of unresolved questions and helps remove barriers to starting clinical trials.

First discovered in the 1990s, scientists now know that CDG is caused by mutations that disrupt the body’s normal process of attaching sugars to proteins. Children with CDG have varying degrees of speech and language difficulty, poor balance, motor control, vision problems, hearing impairments and seizures. 

Because CDG is rare, many patients bounce between doctors and clinics for years before they receive an accurate diagnosis. At the symposium, an innovative session called the “Doctor-is-in” session connects families with medical researchers and clinicians in small groups. For some medical researchers, the session is the first time they have met a person with CDG.

The conference was co-organized by Sanford Burnham Prebys and CDG CARE, a nonprofit organization founded by parents seeking information and support for CDG.

Institute News

How to help children survive—and thrive—after a brain cancer diagnosis

AuthorMonica May
Date

January 13, 2020

Lynne Selinka knew in her heart that something was seriously wrong with her 10-year-old son, Travis. For months he had experienced dizziness, vomiting and headaches, despite his doctor’s best efforts to find a cause. A visit to Rady Children’s Hospital-San Diego revealed a heartbreaking diagnosis: Travis had a malignant brain tumor. He was operated on the next day and then endured two months of radiation treatment followed by six rounds of chemotherapy.

“That year, Travis asked Santa, ‘Can I please be done with chemo before Christmas?’” Lynne said. “It was by far the hardest year of our life.”

Brain tumors are the most common cause of cancer-related death in children—recently surpassing leukemia. To help the public learn about the latest efforts to develop better treatments for pediatric brain cancer, our Institute teamed up with the Fleet Science Center to host a panel discussion on Sunday, December 8. Travis and his parents, Lynne and Tony, shared their story alongside the clinician who treated Travis, John Crawford, MD, director of Pediatric Neuro-Oncology at Rady Children’s Hospital-San Diego; and a scientist working on personalized treatments for pediatric brain cancer, Robert Wechsler-Reya, PhD, of Sanford Burnham Prebys and Rady Children’s Institute for Genomic Medicine. 

As the speakers explained, while aggressive therapies have improved outcomes for children with brain tumors (today Travis is a junior in high school), one in four children with a malignant brain tumor does not survive. Children who do survive have an increased risk of severe long-term side effects from undergoing aggressive treatment at such a young age, including developing additional cancers or experiencing intellectual disability. Six years after he was declared cancer-free, Travis was diagnosed with chronic myeloid leukemia, a type of blood cancer caused by his previous chemotherapy. So far, his new treatment is working.

Wechsler-Reya hopes his work to develop personalized therapies based upon an individual’s tumor could help spare children from this painful experience. By analyzing patient tumor samples—obtained from Rady Children’s Hospital—his team works to understand the cancer at a molecular level, studying the tumor’s DNA mutations, changes in gene expression, responses to drugs, and much more. Armed with this information, the scientists then work to find therapies that are customized to a child’s specific tumor—and may be more effective and less toxic.

“For pediatric brain cancer, success doesn’t just mean better treatments. It also means developing treatments with fewer long-term side effects,” says Wechsler-Reya. “If successful, this work might help more children not only survive brain cancer, but also live a long, healthy life after treatment.

Travis and his family welcome this work with open arms.  

“We try to look for a silver lining in every day. Travis has become an amazing public speaker and now shares his story with other children fighting brain cancer. But each part of our journey has been so hard—from receiving the diagnosis, seeing Travis go through a painful surgery and then chemo, not knowing if the treatments would work, and then being diagnosed with another cancer almost six years later,” said Lynne. “We are so grateful for the efforts of researchers who are working toward a world where a child doesn’t have to go through what Travis did—or at least is spared from some of the hardest parts of the journey.”

This event was the last of our five-part “Cornering Cancer” series at the Fleet Science Center. Read about our past discussions focusing on lung, blood, breast and pancreatic cancers.

Institute News

Sanford Burnham Prebys scientist joins historic effort to help children with rare disease

AuthorMonica May
Date

October 3, 2019

Hudson Freeze, PhD, professor of Human Genetics at Sanford Burnham Prebys, has joined a historic effort that establishes—for the first time—a nationwide network of 10 regional academic centers, Sanford Burnham Prebys researchers and patient advocacy groups to address decades of unresolved questions surrounding congenital disorders of glycosylation, or CDG, a rare disease that affects children. The consortium is funded by a $5 million, five-year grant from the National Institutes of Health (NIH). 

“We are extremely pleased that the NIH is investing in an initiative that will improve the lives of people affected by CDG,” says Freeze, who leads efforts to develop and validate disease biomarkers that will aid in diagnoses, and measuring treatment benefits during clinical trials. “Although globally the number of people living with CDG is relatively small, the impact on the lives of these individuals and their families can be profound. We look forward to working with the patients, families, physicians, scientists and other stakeholders focused on this important study.”

CDG is caused by genetic mutations that disrupt how the body’s sugar chains attach to proteins. First described in the 1990s, today scientists have discovered more than 140 types of mutations that lead to CDG. Symptoms are wide-ranging, but can include developmental delays, movement problems and impaired organ function. Some children may benefit from a sugar-based therapy; however, developing treatments for those who need alternative treatment options has been hindered by a lack of natural history data—tracking the course of the condition over time—comprehensive patient registry, and reliable methods to establish the CDG type.

Working together, the consortium will overcome these hurdles by: 

  • Defining the natural history of CDG through a patient study, validating patient-reported outcomes and sharing CDG knowledge 
  • Developing and validating new biochemical diagnostic techniques and therapeutic biomarkers to use in clinical trials 
  • Evaluating whether dietary treatments restore glycosylation to improve clinical symptoms and quality of life

Freeze will lead the efforts to develop and validate biomarkers for CDG, working alongside the Children’s Hospital of Philadelphia and the Mayo Clinic. The principal investigator of the CDG Consortium Project is Eva Morava, MD, PhD, professor of Medical Genetics at the Mayo Clinic. The patient advocacy groups involved are CDG CARE and NGLY1.org. 

Sanford Burnham Prebys and CDG Care will host the 2020 Rare Disease Day Symposium and CDG Family Conference from February 28 to March 1 in San Diego, which welcomes researchers, clinicians, children with CDG and their families, and additional CDG community members. Register to attend. 
 

Institute News

Sanford Burnham Prebys scientists win two American Cancer Society awards

AuthorMonica May
Date

October 1, 2019

Innovation and Collaboration of the Year Awards

The San Diego cancer community—including oncologists, oncology nurses, radiologists, cancer researchers and their friends and family—gathered on September 22 to celebrate progress made in reducing cancer deaths and recognize exceptional individuals and institutions at the inaugural American Cancer Society’s Celebration of Cancer Care Champions in San Diego.

More than 40 finalists were selected, including Sanford Burnham Prebys professors Robert Wechsler-Reya, PhD, who received the Innovation of the Year award for his team’s creation of a new model for studying a brain tumor that commonly arises in infants; and Jorge Moscat, PhD, and Maria Diaz-Meco, PhD, who received the Collaboration of the Year award for their partnership with clinicians at Scripps Clinic who uncovered a novel way to potentially identify a deadly form of colorectal cancer.

Nominations were reviewed by an independent review committee composed of representatives from 10 leading healthcare and research institutions, including Celgene, Kaiser Permanente, Rady Children’s Hospital, Scripps MD Anderson Cancer Center, Moores Cancer Center at UC San Diego Health and more. (Note: Members of the review committee did not score nominations for their own institutions.)

Read on to learn more about our award-winning research:

Innovation of the Year: A new model for studying brain tumors that strike infants
Robert Wechsler-Reya, PhD, a professor at Sanford Burnham Prebys and program director of the Joseph Clayes III Research Center for Neuro-Oncology and Genomics at the Rady Children’s Institute for Genomic Medicine, was honored for his development of a novel mouse model of a pediatric brain tumor called choroid plexus carcinoma. This tumor most commonly arises in infants under the age of one who are too young to undergo radiation treatment. Until now, drug development has been hindered by the lack of models that could help researchers better understand the cancer. Wechsler-Reya and his team have already used the model to identify potential drug compounds that may be therapeutically useful.

Collaboration of the Year (tie): Novel biomarkers to help detect a deadly colorectal cancer 
Sanford Burnham Prebys professors Jorge Moscat, PhD, and Maria Diaz-Meco, PhD; and Scripps Clinic clinicians Darren Sigal, MD, and Fei Baio, MD, were recognized for their successful collaboration. Together, the researchers revealed that loss of two genes drives the formation of the deadly serrated form of colorectal cancer—yielding promising biomarkers that could identify the tumor type. This insight could lead to the development of a diagnostic test to identify serrated colorectal cancer, a hurdle that previously limited our understanding of this deadly cancer type and the development of effective treatments. The research also identified a combination treatment that has treated the cancer in mice.

Institute News

West Coast meets East Coast: Dr. Wechsler-Reya makes special trip to thank students

AuthorMonica May
Date

July 17, 2019

In the summer of 2015, 5-year-old William Schultz began to experience odd and increasingly worrying symptoms, including frequent vomiting. After two emergency-room visits, doctors ushered his parents, Jim and Margaret Schultz, into a small office and gave an unimaginable diagnosis: William had a brain tumor, ultimately revealed as medulloblastoma—the most common malignant childhood brain cancer. Standard treatment proved ineffective. The tumor returned, and William later died due to treatment complications.

William’s parents quickly channeled their pain into action. Mr. and Mrs. Schultz launched William’s Warriors, a foundation that supports art therapy for all children battling cancer, both in and out of the hospital, and raises funds in support of a cure for pediatric brain cancer—the deadliest form of childhood cancer. Even with aggressive treatment, many children don’t survive, and those who do often suffer severe long-term side effects from the therapy. Half of the foundation’s fundraising goes to William’s Superhero Fund, which supports the work of Robert Wechsler-Reya, PhD, professor and director of the Tumor Initiation and Maintenance Program at Sanford Burnham Prebys, and program director of the Clayes Center for Neuro-Oncology and Genomics at the Rady Children’s Institute for Genomic Medicine.

On May 31, 2019, Wechsler-Reya traveled to New York’s Bay Shore High School, where Mrs. Schultz teaches art—and many teachers and students volunteer with the foundation—to provide an update on his research. As part of his goal to develop safer and more effective treatments for pediatric brain cancer, his lab explores potential personalized treatments based on a child’s specific tumor type, nanotechnology approaches that improve drug delivery and immunotherapy to train patients’ immune systems to eradicate the cancer.

The visit, organized by William’s Warriors volunteer and New York State Master Science Teacher Erin Garland, provided students with a unique opportunity to learn firsthand about the drug development process and how their funds directly impact medical research. During the trip, Wechsler-Reya addressed an assembly of students and teachers, attended a student-centered science symposium, met one-on-one with science students and participated in a question-and-answer session with STEAM teachers. Following his address, the Bay Shore Girls Basketball Team and Brother Sister Organization, presented Wechsler-Reya with a donation of funds they raised in support of his research.

“From the bottom of our hearts, we sincerely thank Dr. Wechsler-Reya for taking time out of his very busy schedule to make this visit. But, more importantly, we are grateful for his unwavering commitment to finding a cure for childhood brain cancer,” says Mrs. Schultz. “While William’s life couldn’t be saved, knowing that researchers are working to find a treatment that might help children like him means the absolute world to us.” 

Read William’s story

Donate to William’s Superhero Fund 

The Bay Shore Girls Basketball Team and Brother Sister Organization presented Wechsler-Reya with a donation of funds they raised in support of his research.

The Bay Shore Girls Basketball Team and Brother Sister Organization presented Wechsler-Reya with a donation of funds they raised in support of his research.

Institute News

Meet Clyde Campbell: A new PhD graduate

AuthorMonica May
Date

June 17, 2019

When Clyde Campbell was 6 years old, his life changed overnight. 

“I went to sleep, and everything was completely normal. But when I woke up, my knee had swollen to three times its usual size and was stuck in a 90-degree position. I learned I had juvenile rheumatoid arthritis, which then spread throughout my body—and no one knew why this had happened.”

Like the adult form, juvenile rheumatoid arthritis occurs when the immune system attacks healthy tissue. But much remains unknown—including the initial trigger that causes the body to misfire—and treatments are limited. This mystery sparked Campbell’s interest in science and desire to understand the ‘why’ behind disease—and thus create better medicines.

After obtaining a bachelor’s degree in molecular biology from UC San Diego, Campbell applied to Sanford Burnham Prebys’ Graduate School in hopes of working with his scientific hero, Duc Dong, PhD, assistant professor in the Human Genetics Program. 
 
“When I completed my work at UC San Diego, everyone spoke highly of Dr. Dong and the thoroughness of his science. I knew very early on that I wanted to work with him,” says Campbell. “Sanford Burnham Prebys’ graduate school was attractive to me because the program allows you to start working with your PhD advisor right away—so I met with Dr. Dong and began my research.”   

Last month, Campbell completed his doctorate, the 40th PhD awarded by the Graduate School.  His thesis, completed under Dong’s guidance, demonstrated his success in reprogramming developing cells within a zebrafish (mesoderm- and ectoderm-derived cells) into the cells that become the pancreas (pancreatic progenitors), an important advance for people with type 1 diabetes (insulin is released from cells in the pancreas). Current cell-based treatments rely upon cadaver-sourced cells, which are effective but are unable to meet patient demand.

Campbell will carry his training and knowledge of cellular differentiation to Iowa State University, where he’s accepted a position as an adjunct associate professor. There, he will continue his regenerative medicine work, with a new focus on blood cell differentiation. This work could lead to treatments for children with leukemia and people battling other blood disorders. As a father to a 3-year-old daughter, his research now takes on special meaning.

“As a society, one of the most important things we can do for future generations is impart new knowledge. With research comes powerful insights—which could lead to cures. One day, I hope no child or adult will have to go through my experience.” 

Learn about Sanford Burnham Prebys’ Graduate School. 

Check out our upcoming SBP Insights event, held on June 20, 2019, which features a doctor, scientist and patient discussing rheumatoid arthritis and other autoimmune diseases.

Interested in keeping up with our latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.

Institute News

Autism researcher raising a son with autism shares his story

AuthorMonica May
Date

April 15, 2019

Twenty years ago, Fumitoshi Irie, PhD, was conducting his postdoctoral research in Tokyo when he noticed his nearly 2-year-old son, Koji, exhibiting unusual behaviors. 

He didn’t talk often, and when he did, it was garbled. He didn’t make eye contact. He performed repetitive motions. As a neuroscientist, Irie’s instincts sent him to the neurology textbooks at the library. There, he found the symptoms aligned perfectly with autism.  

“Our pediatrician confirmed my suspicions. But at the time, autism was not well known in Japan. A diagnostic system didn’t exist yet, and neither did therapy or other services,” says Irie, now a research assistant professor at Sanford Burnham Prebys in the laboratory of Yu Yamaguchi, MD, PhD “Our doctor told us that the best resources for our son were in the U.S.”

Luckily, moving to America was a natural next step for Irie’s scientific career. He and his wife decided to move to California to join Yamaguchi’s laboratory. He’s worked at Sanford Burnham Prebys ever since. 

“Now, we have great providers and are very happy about the services in San Diego. But I will admit those first years were stressful,” recounts Irie. “Everything changed. We didn’t speak English very well and we didn’t know the right people to contact. It took us a few years to get settled.” 

Autism, also known as autism spectrum disorder (ASD), is a developmental disorder that affects communication and behavior. Symptoms can range from very mild to severe. Approximately 1 in 59 children are diagnosed with autism, according to the Centers for Disease Control and Prevention (CDC), with boys four times more likely to be diagnosed than girls. While the cause of autism is currently unknown, some studies indicate that genetics are involved. However, more research is needed to form a conclusive answer. 

“It’s unlikely that a single gene mutation causes autism,” says Irie. “Multiple factors are likely involved, which explains why the condition appears as a spectrum disorder.” 

A mother’s call sparks new research    

Irie’s autism research originated from an unexpected place: a phone call from a woman named Sarah Ziegler whose son has a rare disease called multiple hereditary exostoses (MHE) that causes numerous bone tumors in children. As the co-founder of the MHE Research Foundation, she noticed that children with MHE often displayed autistic behaviors. 

Irie and Yamaguchi were studying the genes that cause the rare disease, EXT1 and EXT2. These genes are necessary to produce heparan sulfate, a long sugar “tree” that dangles off of the edge of cells and clasps important proteins and molecules. After Sarah’s observation, they began looking into potential connections to autism. 

For Irie, it was a welcome opportunity to study the condition that had changed his life.

First, he created a mouse model that allowed control over the timing and location of EXT1 expression, called a conditional knock out mouse. When he applied a “social reunion test,” in which mice are separated and their behavior post-reunion is studied, he found the reunited mice that lacked EXT1 didn’t interact with each other normally. They co-existed peacefully but didn’t sniff each other and cuddle as they did before. This finding was published in a 2014 paper in the Proceedings of the National Academic of Sciences (PNAS).

Now, Irie is unraveling the molecular dynamics behind this behavior. He’s focused on determining which molecules and proteins interact with heparan sulfate, with a particular focus on the molecular messages sent between neurons. 

Hope for new insights

Irie is quick to note there are caveats to his research: Autism is a spectrum disorder so this may not apply to all children, and heparan sulfate is expressed on many cells and regulates many functions so it is unlikely to be a good target for a potential medicine. 

However, he hopes his research could reveal new insights into autism. While heparan sulfate may not be the right medicinal target, it’s possible there is a protein or still-unknown-factor that interacts with the heparan sulfate “tree” and could be the clue that leads to a drug candidate.  

Today, Irie’s son is almost 22 years old. He lives at home and enjoys participating in a job training program that is organized by the San Diego School District. 

“I love my son just the way he is,” Irie says. “At the same time, I welcome approaches that could ease his suffering because of hypersensitivity or anxiety. Often, everyday experiences are painful to him, such as the sound of a door closing, and it would be wonderful to make that easier for him to bear.”  

Interested in keeping up with our latest discoveries, upcoming events and more? Subscribe to our monthly newsletter, Discoveries.